BIRC5 and renal cell carcinoma: It was also reported that vorinostat (an HDAC inhibitor) enhances the activity of temsirolimus (an mTOR inhibitor) in a panel of RCC cell lines as well as RCC xenografts through suppression of survivin levels [31].